MRK Merck & Co., Inc.
MRK Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 2 bull converging
POC $121.03 · VWAP $117.27 · +24.5% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP + 4 others sold $30M, Aug 7–13
Coverage
2 watchlists
MRK Price Structure
Loading timeframes…
Peers
Every watchlist MRK belongs to, members best 30-day change first — MRK highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare-scan
@healthcare
Reported the quarter ending 2026-06-30: revenue $16.61B, diluted EPS -$0.54, net income -$1.33B (SEC filing). Across the print the stock moved +0.4% (close before → first close after).
full note →Against street estimates
How MRK's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
MRK research tape
81 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.